

**GOVERNMENT OF INDIA
MINISTRY OF SCIENCE & TECHNOLOGY
DEPARTMENT OF BIOTECHNOLOGY**

LOK SABHA

UNSTARRED QUESTION NO. 2829

TO BE ANSWERED ON 11/05/2016

MEDICINES MANUFACTURED THROUGH BIOTECHNOLOGY

2829. SHRI KUNWAR PUSHPENDRA SINGH CHANDEL:
SHRI ASADUDDIN OWAIISI

Will the Minister of SCIENCE AND
TECHNOLOGY be pleased to state:

विज्ञान और प्रौद्योगिकी मंत्री

- (a) whether the Government has reviewed the side-effects, if any, of the use of medicines manufactured through biotechnology;
- (b) if so, the details and the outcome thereof;
- (c) whether the Government has constituted any team of experts for assessing the impact of use of the said medicines on the supply of generic drugs;
- (d) if so, the details thereof and the outcome therefrom;
- (e) whether the kit called AINA is to be marketed shortly; and
- (f) if so, the details of the benefits of this kit and cost at which it is available / likely to be made available to the general public alongwith the other innovations likely to be put in the market developed by the Department of Biotechnology?

ANSWER

MINISTER OF STATE FOR SCIENCE & TECHNOLOGY AND EARTH SCIENCES
(Y. S. CHOWDARY)

विज्ञान और प्रौद्योगिकी तथा पृथ्वी विज्ञान राज्य मंत्री
(वाई. एस. चौधरी)

(a) & (b) Yes, Madam. The safety of medicines manufactured through biotechnology is reviewed during Phase-I to Phase-III clinical trials depending on the nature of medicine i.e. new biological entity or biosimilar. Marketing authorization is granted after successful completion of Phase-III clinical trials. Subsequent pharmacovigilance studies are also reviewed to continue market authorization. So far no medicine manufactured through biotechnology is withdrawn during pharmacovigilance studies.

(c) No Madam.

(d) Does not arise.

